Pieter C Vogelaar1,2, Maurits Roorda1, Edwin L de Vrij1, Martin C Houwertjes3, Maaike Goris1, Hjalmar Bouma1,4, Adrianus C van der Graaf2, Guido Krenning2,5, Robert H Henning1. 1. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2. Sulfateq B.V., Groningen, The Netherlands. 3. Department of Anesthesiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 4. Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 5. Cardiovascular Regenerative Medicine, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
Background: Mitochondrial dysfunction plays an important role in kidney damage in various pathologies, including acute and chronic kidney injury and diabetic nephropathy. In addition to the well-studied ischaemia/reperfusion (I/R) injury, hypothermia/rewarming (H/R) also inflicts acute kidney injury. Substituted 6-hydroxychromanols are a novel class of mitochondrial medicines that ameliorate mitochondrial oxidative stress and protect the mitochondrial network. To identify a novel 6-hydroxychromanol that protects mitochondrial structure and function in the kidney during H/R, we screened multiple compounds in vitro and subsequently assessed the efficacy of the 6-hydroxychromanol derivatives SUL-109 and SUL-121 in vivo to protect against kidney injury after H/R in rats. Methods: Human proximal tubule cell viability was assessed following exposure to H/R for 48/4 h in the presence of various 6-hydroxychromanols. Selected compounds (SUL-109, SUL-121) or vehicle were administered to ketamine-anaesthetized male Wistar rats (IV 135 µg/kg/h) undergoing H/R at 15°C for 3 h followed by rewarming and normothermia for 1 h. Metabolic parameters and body temperature were measured throughout. In addition, renal function, renal injury, histopathology and mitochondrial fitness were assessed. Results: H/R injury in vitro lowered cell viability by 94 ± 1%, which was counteracted dose-dependently by multiple 6-hydroxychomanols derivatives. In vivo, H/R in rats showed kidney injury molecule 1 expression in the kidney and tubular dilation, accompanied by double-strand DNA breaks and protein nitrosylation. SUL-109 and SUL-121 ameliorated tubular kidney damage, preserved mitochondrial mass and maintained cortical adenosine 5'-triphosphate (ATP) levels, although SUL-121 did not reduce protein nitrosylation. Conclusions: The substituted 6-hydroxychromanols SUL-109 and SUL-121 ameliorate kidney injury during in vivo H/R by preserving mitochondrial mass, function and ATP levels. In addition, both 6-hydroxychromanols limit DNA damage, but only SUL-109 also prevented protein nitrosylation in tubular cells. Therefore SUL-109 offers a promising therapeutic strategy to preserve kidney mitochondrial function.
Background: Mitochondrial dysfunction plays an important role in kidney damage in various pathologies, including acute and chronic kidney injury and diabetic nephropathy. In addition to the well-studied ischaemia/reperfusion (I/R) injury, hypothermia/rewarming (H/R) also inflicts acute kidney injury. Substituted 6-hydroxychromanols are a novel class of mitochondrial medicines that ameliorate mitochondrial oxidative stress and protect the mitochondrial network. To identify a novel 6-hydroxychromanol that protects mitochondrial structure and function in the kidney during H/R, we screened multiple compounds in vitro and subsequently assessed the efficacy of the 6-hydroxychromanol derivatives SUL-109 and SUL-121 in vivo to protect against kidney injury after H/R in rats. Methods:Human proximal tubule cell viability was assessed following exposure to H/R for 48/4 h in the presence of various 6-hydroxychromanols. Selected compounds (SUL-109, SUL-121) or vehicle were administered to ketamine-anaesthetized male Wistar rats (IV 135 µg/kg/h) undergoing H/R at 15°C for 3 h followed by rewarming and normothermia for 1 h. Metabolic parameters and body temperature were measured throughout. In addition, renal function, renal injury, histopathology and mitochondrial fitness were assessed. Results: H/R injury in vitro lowered cell viability by 94 ± 1%, which was counteracted dose-dependently by multiple 6-hydroxychomanols derivatives. In vivo, H/R in rats showed kidney injury molecule 1 expression in the kidney and tubular dilation, accompanied by double-strand DNA breaks and protein nitrosylation. SUL-109 and SUL-121 ameliorated tubular kidney damage, preserved mitochondrial mass and maintained cortical adenosine 5'-triphosphate (ATP) levels, although SUL-121 did not reduce protein nitrosylation. Conclusions: The substituted 6-hydroxychromanolsSUL-109 and SUL-121 ameliorate kidney injury during in vivo H/R by preserving mitochondrial mass, function and ATP levels. In addition, both 6-hydroxychromanols limit DNA damage, but only SUL-109 also prevented protein nitrosylation in tubular cells. Therefore SUL-109 offers a promising therapeutic strategy to preserve kidney mitochondrial function.
Authors: Marziyeh Tolouee; Koen D W Hendriks; Fia Fia Lie; Lucas P Gartzke; Maaike Goris; Femke Hoogstra-Berends; Steven Bergink; Robert H Henning Journal: Cell Transplant Date: 2022 Jan-Dec Impact factor: 4.139
Authors: D Nakladal; H Buikema; A Reyes Romero; S P H Lambooy; J Bouma; G Krenning; P Vogelaar; A C van der Graaf; M R Groves; J Kyselovic; R H Henning; L E Deelman Journal: Sci Rep Date: 2019-01-09 Impact factor: 4.379
Authors: Ruta Zulpaite; Povilas Miknevicius; Bettina Leber; Kestutis Strupas; Philipp Stiegler; Peter Schemmer Journal: Front Med (Lausanne) Date: 2021-12-24
Authors: Lei Wang; Charlotte E Pelgrim; Daniël H Swart; Guido Krenning; Adrianus C van der Graaf; Aletta D Kraneveld; Thea Leusink-Muis; Ingrid van Ark; Johan Garssen; Gert Folkerts; Saskia Braber Journal: Int J Mol Sci Date: 2021-05-08 Impact factor: 5.923
Authors: Koen D W Hendriks; Christian P Joschko; Femke Hoogstra-Berends; Janette Heegsma; Klaas-Nico Faber; Robert H Henning Journal: Int J Mol Sci Date: 2020-03-09 Impact factor: 5.923